EMA to review Dynax Heplisav marketing authorization application
Heplisav is indicated for immunization against infection caused by all known subtypes of hepatitis B virus in people aged 18 through 70 years of age and in patients
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.